News

• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs
• Revlimid (lenalidomide) generics launch across Europe

Research

• Pricing and reimbursement of medicines in Canada
• Medicines pricing conditions in Italy and Brazil: comparison of regulations
• Relevance of NTI to the treatment of epilepsy
• What is the meaning of a narrow therapeutic index?

General

• FDA releases one-year progress report for the Generic Drug Cluster
• Pharmaceutical manufacturing companies in Brazil
• Pharmaceutical companies in Argentina
• Pharmaceutical companies in Latin America and the Caribbean

News

• Australia and EU: Alvotech Humira and Stada Lucentis biosimilars approved
• Advances for Alvotech’s partnerships in Japan, Canada and Switzerland
• Progress for Lucentis (ranibizumab) biosimilars in Europe and the US
• Bevacizumab biosimilar approvals and launch in Japan and USA

Research

• Investigating biosimilar product drift and divergence
• Biosimilars, are they comparable to their reference counterparts?
• The cost savings of non-medical switching in dermatology
• Switching from adalimumab originator and ABP501 to SB5 in arthritis patients

General

• Key facts of biosimilars approval regulation in Brazil
• Canada’s Saskatchewan province introduces biosimilars switching policy
• A Canadian gastro-enterologist’s view on advising on biosimilars
• Biosimilars approved in the US

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links